Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes Detection for Anlotinib Efficacy in NSCLC
NCT05218759Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Open-label trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05218759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218759.